(1 - 39 from 82
)
How Is Triple Negative Breast Cancer Different from Other Diagnoses?www.self.com › Health › breast cancer
www.self.com
May 31, · Doctors used to treat all cases of triple negative breast cancer as just one group, but that's changing, Rita Nanda, M.D., ...
ASCO 2017: Addition of Pembrolizumab to JNCCN 360jnccn360.org › breast › news › asco addition-of-pe...
jnccn360.org
... improved pathologic complete response rates in patients with HER2-negative breast cancer, based on the results of the I-SPY 2 trial presented by Rita Nanda, ...
Data shows immunotherapy promise in breast cancer - PharmaTimes
www.pharmatimes.com
Already approved for metastatic melanoma, Merck & Co’s Keytruda has shown promising activity for difficult-to-treat triple-negative breast cancer
Pembrolizumab induced durable responses in metastatic triple-negative...
www.healio.com
“There are no approved targeted therapies to treat metastatic triple-negative breast cancer, and the median survival for patients with this disease is approximately 1 year,” said Rita Nanda, MD, assistant professor of medicine and associate director of the Breast Medical Oncology Program at the University of ...
sorted by relevance / date